Market Summary
USD14.99+0.47
Market Closed3.24%
ACOR Stock Price
ACOR RSI Chart
ACOR Valuation
ACOR Price/Sales (Trailing)
ACOR Profitability
ACOR Fundamentals
ACOR Revenue
ACOR Earnings
Price Action
52 Week Range
0.2818.20
(Low)(High)
Last 7 days
-4.0%
Last 30 days
29.8%
Last 90 days
15.2%
Trailing 12 Months
5317.4%
ACOR Financial Health
ACOR Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ACOR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-17 | COHEN RON | bought | 6,500 | 0.65 | 10,000 | president and ceo |
2023-03-16 | COHEN RON | bought | 6,093 | 0.6 | 10,156 | president and ceo |
2022-09-03 | Clem Kerry M | sold (taxes) | -601 | 0.398 | -1,511 | chief commercial officer |
2022-09-03 | Sabella Lauren M | sold (taxes) | -601 | 0.398 | -1,511 | chief operating officer |
2022-03-17 | COHEN RON | sold | -3,894 | 1.7014 | -2,289 | president and ceo |
2021-09-03 | Morales Robert | sold (taxes) | -1,962 | 4.38 | -448 | interim pao & pfo |
2021-09-03 | Sabella Lauren M | sold (taxes) | -6,618 | 4.38 | -1,511 | chief commercial officer |
2021-09-03 | COHEN RON | sold (taxes) | -17,257 | 4.38 | -3,940 | president and ceo |
2021-03-03 | BLANK BURKHARD | acquired | - | - | 11,125 | cmo and head of r&d |
2021-03-03 | Sabella Lauren M | acquired | - | - | 11,125 | chief commercial officer |
Which funds bought or sold ACOR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | sold off | -100 | -1,009,720 | - | -% |
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | new | - | 716,885 | 716,885 | 0.02% |
2023-08-21 | OSAIC HOLDINGS, INC. | new | - | 13.00 | 13.00 | -% |
2023-08-21 | ADVISOR GROUP HOLDINGS, INC. | sold off | -100 | - | - | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | new | - | 48,657 | 48,657 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | sold off | -100 | -43,804 | - | -% |
2023-08-14 | Royal Bank of Canada | new | - | 7,000 | 7,000 | -% |
2023-08-14 | DEUTSCHE BANK AG\ | new | - | 22,117 | 22,117 | -% |
2023-08-14 | Royal Bank of Canada | sold off | -100 | - | - | -% |
2023-08-14 | VANGUARD GROUP INC | sold off | -100 | -93,630 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Acorda Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 10, 2023 | davidson kempner capital management lp | 0.13% | 31,311 | SC 13D/A | |
| Mar 10, 2023 | davidson kempner capital management lp | 0.21% | 51,189 | SC 13D/A | |
| Feb 14, 2023 | canyon capital advisors llc | 0.00% | 0 | SC 13G/A | |
| Feb 13, 2023 | renaissance technologies llc | 3.57% | 868,892 | SC 13G/A | |
| Jan 23, 2023 | davidson kempner capital management lp | 0.24% | 59,129 | SC 13D/A | |
| Jun 10, 2022 | soros fund management llc | 0% | 0 | SC 13G | |
| Jun 10, 2022 | davidson kempner capital management lp | 0.28% | 68,229 | SC 13D | |
| Feb 14, 2022 | ubs oconnor llc | 0% | 0 | SC 13G/A | |
| Feb 14, 2022 | point72 asset management, l.p. | 4.1% | 464,276 | SC 13G/A | |
| Feb 14, 2022 | canyon capital advisors llc | 5.79% | 649,031 | SC 13G/A |
Recent SEC filings of Acorda Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 09, 2023 | 10-Q | Quarterly Report | |
| Aug 08, 2023 | 8-K | Current Report | |
| Jun 27, 2023 | 8-K | Current Report | |
| Jun 26, 2023 | 8-K | Current Report |
Peers (Alternatives to Acorda Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 143.8B | 26.6B | 4.22% | 19.52% | 18.02 | 5.41 | 0.75% | 21.34% |
GILD | 93.5B | 27.4B | -3.50% | 20.95% | 17.04 | 3.41 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -11.43% | -12.52% | 32.6 | 3.69 | -53.67% | -91.41% |
BIIB | 37.2B | 10.0B | -3.81% | -2.75% | 13.96 | 3.73 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.0B | 1.7B | 3.79% | 9.48% | 62.24 | 6.56 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -13.26% | 158.53% | -7.29 | 48.33 | 54.84% | -12.96% |
DNLI | 2.8B | - | -11.57% | -29.57% | -22.07 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 2.30% | -49.37% | -5.73 | 23.39 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.3B | 121.2M | -10.65% | -29.69% | -4.65 | 11.03 | -70.36% | -531.73% |
REPL | 1.0B | 15.3M | -19.06% | 2.95% | -5.55 | 65.91 | 1090.59% | -36.57% |
NVAX | 682.8M | 1.6B | -13.40% | -61.01% | -1.16 | 0.43 | 23.74% | 60.24% |
FATE | 208.9M | - | -19.70% | -90.51% | -0.99 | 1.53 | 116.83% | 16.61% |
VXRT | 114.6M | 2.1M | -6.34% | -64.60% | -1.14 | 55.76 | 487.70% | -8.66% |
SGMO | 104.6M | - | -36.73% | -87.68% | -0.53 | 0.43 | 113.96% | -15.19% |
IBIO | 6.2M | - | -2.07% | -93.34% | -0.08 | 3.21 | - | -129.46% |
Acorda Therapeutics News
Returns for ACOR
Cumulative Returns on ACOR
-23.3%
10-Year Cumulative Returns
-26.2%
7-Year Cumulative Returns
-33.8%
5-Year Cumulative Returns
64.9%
3-Year Cumulative Returns
Risks for ACOR
What is the probability of a big loss on ACOR?
100%
Probability that Acorda Therapeutics stock will be more than 20% underwater in next one year
100%
Probability that Acorda Therapeutics stock will be more than 30% underwater in next one year.
100%
Probability that Acorda Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ACOR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Acorda Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -1.2% | 116,914,000 | 118,290,000 | 118,566,000 | 124,063,000 | 122,008,000 | 122,742,000 | 129,071,000 | 130,263,000 | 151,897,000 | 153,730,000 | 152,967,000 | 165,303,000 | 159,935,000 | 176,370,000 | 192,408,000 | 211,064,000 | 306,156,000 | 409,405,000 | 471,433,000 | 590,679,000 | 588,930,000 |
| Costs and Expenses | -7.9% | 136,744,000 | 148,403,000 | 153,906,000 | 171,229,000 | 187,194,000 | 189,702,000 | 208,109,000 | 276,137,000 | 258,725,000 | 254,419,000 | 231,043,000 | 150,500,000 | 420,519,000 | 450,793,000 | 504,040,000 | 586,483,000 | 393,928,000 | 414,753,000 | 432,947,000 | 720,971,000 | 749,678,000 |
| S&GA Expenses | -8.1% | 93,590,000 | 101,832,000 | 106,256,000 | 108,442,000 | 115,068,000 | 117,369,000 | 124,399,000 | 128,835,000 | 139,147,000 | 145,435,000 | 152,576,000 | 160,923,000 | 169,690,000 | 181,229,000 | 192,846,000 | 188,441,000 | 183,310,000 | 177,378,000 | 172,254,000 | 174,954,000 | 172,124,000 |
| R&D Expenses | 0.5% | 5,521,000 | 5,496,000 | 5,804,000 | 5,968,000 | 6,516,000 | 7,365,000 | 10,420,000 | 13,377,000 | 17,175,000 | 20,056,000 | 23,012,000 | 27,712,000 | 38,056,000 | 51,760,000 | 60,083,000 | 78,118,000 | 84,900,000 | 91,851,000 | 106,383,000 | 114,467,000 | 124,898,000 |
| EBITDA | -100.0% | - | 32,552,000 | 27,762,000 | -12,640,000 | -30,149,000 | -33,002,000 | -45,086,000 | -110,011,000 | -68,507,000 | -60,219,000 | -35,795,000 | 112,529,000 | -163,486,000 | -176,584,000 | -217,803,000 | -343,945,000 | -62,804,000 | 12,367,000 | 53,499,000 | -113,048,000 | -141,376,000 |
| EBITDA Margin | -100.0% | - | 0.28 | 0.23 | -0.10 | -0.25 | -0.27 | -0.35 | -0.84 | -0.45 | -0.39 | -0.23 | 0.68 | -1.02 | -1.00 | -1.13 | -1.63 | -0.21 | 0.03 | 0.11 | -0.19 | -0.24 |
| Interest Expenses | 1.0% | 30,508,000 | 30,209,000 | 30,200,000 | 29,839,000 | 29,541,000 | 29,772,000 | 30,035,000 | 30,461,000 | 31,054,000 | 30,833,000 | 30,574,000 | 28,380,000 | 25,120,000 | 23,014,000 | 21,872,000 | 21,573,000 | 22,488,000 | 22,524,000 | 21,597,000 | 21,207,000 | 19,972,000 |
| Earnings Before Taxes | 29.4% | -21,072,000 | -29,845,000 | -35,247,000 | -75,720,000 | -93,458,000 | -96,734,000 | -109,074,000 | -176,333,000 | -137,345,000 | -130,800,000 | -107,667,000 | 43,354,000 | -228,976,000 | -239,398,000 | -274,248,000 | -392,576,000 | -105,001,000 | -23,176,000 | 20,423,000 | -149,123,000 | -179,507,000 |
| EBT Margin | 100.0% | - | -0.25 | -0.30 | -0.61 | -0.77 | -0.79 | -0.85 | -1.35 | -0.90 | -0.85 | -0.70 | 0.26 | -1.43 | -1.36 | -1.43 | -1.86 | -0.34 | -0.06 | 0.04 | -0.25 | -0.30 |
| Net Income | 64.1% | -20,917,000 | -58,218,000 | -65,916,000 | -105,625,000 | -118,842,000 | -95,024,000 | -103,954,000 | -166,440,000 | -132,022,000 | -126,579,000 | -99,600,000 | 49,114,000 | -221,768,000 | -231,833,000 | -272,966,000 | -329,031,000 | -79,407,000 | -5,724,000 | 33,682,000 | -146,977,000 | -158,261,000 |
| Net Income Margin | 100.0% | - | -0.49 | -0.56 | -0.85 | -0.97 | -0.77 | -0.81 | -1.28 | -0.87 | -0.82 | -0.65 | 0.30 | -1.39 | -1.31 | -1.42 | -1.56 | -0.26 | -0.01 | 0.07 | -0.25 | -0.27 |
| Free Cashflow | 100.0% | - | -14,441,000 | -21,060,000 | -26,887,000 | -34,033,000 | -28,273,000 | -41,513,000 | -43,620,000 | -37,365,000 | -51,288,000 | -65,396,000 | -91,969,000 | -132,707,000 | -157,466,000 | -218,593,000 | -216,270,000 | -106,358,000 | -8,580,000 | 117,465,000 | 197,798,000 | 181,521,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -2.7% | 365 | 375 | 396 | 393 | 406 | 424 | 455 | 466 | 491 | 584 | 633 | 710 | 728 | 754 | 800 | 880 | 1,197 | 1,234 | 1,300 | 1,311 | 1,251 |
| Current Assets | -4.7% | 65.00 | 68.00 | 82.00 | 72.00 | 77.00 | 80.00 | 102 | 97.00 | 113 | 190 | 221 | 152 | 158 | 168 | 201 | 314 | 358 | 418 | 528 | 547 | 495 |
| Cash Equivalents | -16.5% | 25.00 | 30.00 | 38.00 | 21.00 | 23.00 | 32.00 | 46.00 | 36.00 | 46.00 | 117 | 71.00 | 58.00 | 41.00 | 32.00 | 62.00 | 120 | 148 | 197 | 294 | 321 | 243 |
| Inventory | 9.9% | 15.00 | 13.00 | 13.00 | 15.00 | 15.00 | 15.00 | 19.00 | 21.00 | 25.00 | 27.00 | 29.00 | 30.00 | 33.00 | 26.00 | 25.00 | 27.00 | 28.00 | 31.00 | 29.00 | - | - |
| Net PPE | -9.2% | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 6.00 | 7.00 | 139 | 142 | 143 | 143 | 131 | 113 | 83.00 | 61.00 | 52.00 | 43.00 |
| Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 281 | 280 | 282 | 283 | 284 |
| Current Liabilities | -12.5% | 30.00 | 35.00 | 38.00 | 42.00 | 41.00 | 46.00 | 54.00 | 68.00 | 68.00 | 133 | 137 | 139 | 138 | 71.00 | 86.00 | 92.00 | 94.00 | 97.00 | 140 | 136 | 121 |
| Shareholder's Equity | -11.8% | 68.00 | 77.00 | 94.00 | 76.00 | 88.00 | 128 | 151 | 164 | 190 | 206 | 238 | 314 | 291 | 307 | 311 | 281 | 545 | 567 | 612 | 599 | 607 |
| Retained Earnings | -1.0% | -962 | -953 | -936 | -955 | -941 | -894 | -870 | -849 | -822 | -799 | -766 | -683 | -690 | -673 | -666 | -732 | -468 | -441 | -393 | -403 | -389 |
| Additional Paid-In Capital | 0.0% | 1,030 | 1,030 | 1,030 | 1,030 | 1,029 | 1,024 | 1,023 | 1,016 | 1,016 | 1,008 | 1,008 | 1,000 | 983 | 981 | 979 | 1,015 | 1,012 | 1,009 | 1,005 | 1,000 | 993 |
| Shares Outstanding | 2.1% | 1.00 | 1.00 | - | 1.00 | 1.00 | 1.00 | - | 1.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 20.7% | -11.35 | -14.30 | -20.92 | -26.75 | -33.92 | -28.10 | -41.35 | -43.14 | -37.03 | -49.11 | -61.01 | -73.88 | -95.33 | -89.45 | -128 | -129 | -26.55 | 45.00 | 151 | 224 | 197 |
| Share Based Compensation | -31.8% | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 6.00 | 7.00 | 8.00 | 9.00 | 10.00 | 13.00 | 14.00 | 17.00 | 18.00 | 19.00 | 21.00 | 24.00 | 25.00 |
| Cashflow From Investing | - | - | - | -0.14 | -0.26 | -0.11 | -0.18 | 74.00 | 79.00 | 99.00 | 122 | 59.00 | 110 | 87.00 | 29.00 | -0.50 | -71.33 | -70.77 | -83.41 | -176 | -162 | -161 |
| Cashflow From Financing | - | - | - | - | - | - | - | -69.65 | -69.65 | -69.74 | -0.74 | -1.67 | -61.54 | -61.45 | -61.49 | -60.55 | -0.62 | 2.00 | 11.00 | 13.00 | 67.00 | 66.00 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 2.00 | 2.00 |
ACOR Income Statement
2023-06-30Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total net revenues | $ 29,675 | $ 31,051 | $ 51,933 | $ 53,585 |
| Costs and expenses: | ||||
| Cost of sales | 3,065 | 8,800 | 6,299 | 14,768 |
| Research and development | 1,550 | 1,525 | 2,936 | 3,219 |
| Selling, general and administrative | 21,825 | 30,067 | 44,339 | 57,005 |
| Amortization of intangible assets | 7,691 | 7,691 | 15,382 | 15,382 |
| Change in fair value of derivative liability | (7) | (37) | ||
| Changes in fair value of acquired contingent consideration | (824) | (3,110) | (1,915) | (6,133) |
| Total operating expenses | 33,307 | 44,966 | 67,041 | 84,204 |
| Operating loss | (3,632) | (13,915) | (15,108) | (30,619) |
| Other income (expense), net: | ||||
| Interest and amortization of debt discount expense | (7,773) | (7,474) | (15,344) | (15,036) |
| Interest income | 58 | 20 | 151 | 21 |
| Other income | 2 | 1,250 | 94 | 1,250 |
| Realized loss on foreign currency transactions | (1) | (1) | ||
| Total other expense, net | (7,714) | (6,204) | (15,100) | (13,765) |
| Loss before taxes | (11,346) | (20,119) | (30,208) | (44,384) |
| Benefit from (provision for) income taxes | 1,965 | (26,563) | 4,003 | (26,821) |
| Net loss | $ (9,381) | $ (46,682) | $ (26,205) | $ (71,205) |
| Net loss per share—basic | $ (7.55) | $ (54.01) | $ (21.10) | $ (97.33) |
| Net loss per share—diluted | $ (7.55) | $ (54.01) | $ (21.10) | $ (97.33) |
| Weighted average common shares outstanding used in computing net loss per share-basic | 1,242 | 864 | 1,242 | 732 |
| Weighted average common shares outstanding used in computing net loss per share-diluted | 1,242 | 864 | 1,242 | 732 |
| Net Product Revenues | ||||
| Revenues: | ||||
| Total net revenues | $ 25,965 | $ 27,484 | $ 44,684 | $ 46,059 |
| Royalty Revenues | ||||
| Revenues: | ||||
| Total net revenues | 3,687 | $ 3,567 | 7,215 | $ 7,526 |
| License revenues | ||||
| Revenues: | ||||
| Total net revenues | $ 23 | $ 34 | ||
ACOR Balance Sheet
2023-06-30Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 25,270 | $ 37,536 |
| Restricted cash | 828 | 6,884 |
| Trade accounts receivable, net of allowances of $875 and $842, as of June 30, 2023 and December 31, 2022, respectively | 13,390 | 13,866 |
| Prepaid expenses | 5,480 | 4,312 |
| Inventory, net | 14,797 | 12,752 |
| Other current assets | 5,149 | 6,765 |
| Total current assets | 64,914 | 82,115 |
| Property and equipment, net of accumulated depreciation | 2,163 | 2,603 |
| Intangible assets, net of accumulated amortization | 289,700 | 305,087 |
| Right of use asset, net of accumulated amortization | 4,765 | 5,287 |
| Restricted cash | 255 | 255 |
| Other non-current assets | 2,899 | 248 |
| Total assets | 364,696 | 395,595 |
| Current liabilities: | ||
| Accounts payable | 3,175 | 9,809 |
| Accrued expenses and other current liabilities | 21,822 | 23,680 |
| Current portion of lease liabilities | 1,567 | 1,545 |
| Current portion of acquired contingent consideration | 3,274 | 2,532 |
| Deferred revenue | 548 | 384 |
| Total current liabilities | 30,386 | 37,950 |
| Convertible senior notes | 176,164 | 167,031 |
| Non-current portion of acquired contingent consideration | 35,226 | 38,668 |
| Non-current portion of lease liabilities | 3,764 | 4,341 |
| Deferred tax liability | 39,556 | 44,202 |
| Other non-current liabilities | 11,732 | 9,781 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at June 31, 2023 and December 31, 2022; no shares issued as of June 30, 2023 and December 31, 2022, respectively | ||
| Common stock, $0.001 par value per share. Authorized 3,083,333 shares at June 30, 2023 and December 31, 2022; issued 1,242,376 shares,including those held in treasury, as of June 30, 2023 and December 31, 2022, respectively | 1 | 24 |
| Treasury stock at cost (278 shares at June 30, 2023 and December 31, 2022) | (638) | (638) |
| Additional paid-in capital | 1,030,103 | 1,029,881 |
| Accumulated deficit | (962,478) | (936,273) |
| Accumulated other comprehensive income | 880 | 628 |
| Total stockholders’ equity | 67,868 | 93,622 |
| Total liabilities and stockholders’ equity | $ 364,696 | $ 395,595 |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.